Abstract
We present allele frequencies involving 39 pharmacogenetic biomarkers studied in Brazil, and their distribution on self-reported race/color categories that: (1) involve a mix of perceptions about ancestry, morphological traits, and cultural/identity issues, being social constructs pervasively used in Brazilian society and medical studies; (2) are associated with disparities in access to health services, as well as in their representation in genetic studies, and (3), as we report here, explain a larger portion of the variance of pharmaco-allele frequencies than geography. We integrated a systematic review of studies on healthy volunteers (years 1968–2017) and the analysis of allele frequencies on three population-based cohorts from northeast, southeast, and south, the most populated regions of Brazil. Cross-validation of results from these both approaches suggest that, despite methodological heterogeneity of the 120 studies conducted on 51,747 healthy volunteers, allele frequencies estimates from systematic review are reliable. We report differences in allele frequencies between color categories that persist despite the homogenizing effect of >500 years of admixture. Among clinically relevant variants: CYP2C9*2 (null), CYP3A5*3 (defective), SLCO1B1-rs4149056(C), and VKORC1-rs9923231(A) are more frequent in Whites than in Blacks. Brazilian Native Americans show lower frequencies of CYP2C9*2, CYP2C19*17 (increased activity), and higher of SLCO1B1-rs4149056(C) than other Brazilian populations. We present the most current and informative database of pharmaco-allele frequencies in Brazilian healthy volunteers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kehdy FSG, Gouveia MH, Machado M, Magalhães WCS, Horimoto AR, Horta BL, et al. Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci USA. 2015;112:8696–701.
Lima-Costa MF, Rodrigues LC, Barreto ML, Gouveia M, Horta BL, Mambrini J, et al. Genomic ancestry and ethnoracial self-classification based on 5,871 community-dwelling Brazilians (The Epigen Initiative). Sci Rep. 2015;5:9812.
Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharm J. 2014;14:217–22.
Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet. 2011;20:528–40.
Limdi NA, Brown TM, Yan Q, Thigpen JL, Shendre A, Liu N, et al. Race influences warfarin dose changes associated with genetic factors. Blood. 2015;126:539–45.
Suarez-Kurtz G, Struchiner CJ. Differential effects of predictors of warfarin dose according to race/color categories in the admixed Brazilian population. Pharmacogenet Genomics. 2017;27:210–1.
Pena SDJ, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FDSG, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE. 2011;6:e17063.
Osório RG. O sistema classificatório de ‘cor ou raça’ do IBGE. 2003. http://www.ipea.gov.br/portal/images/stories/PDFs/TDs/td_0996.pdf. Accessed 7 Mar 2016.
Telles EE. Race in another America: the significance of skin color in Brazil. Princeton University Press; 2004.
Zineh I, Pacanowski MA. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration. Pharmacotherapy. 2011;31:729–35.
Chen JJ, Lin W-J, Chen H-C. Pharmacogenomic biomarkers for personalized medicine. Pharmacogenomics. 2013;14:969–80.
Van Driest SL, Shi Y, Bowton EA, Schildcrout JS, Peterson JF, Pulley J, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95:423–31.
Céspedes-Garro C, Naranjo M-EG, Ramírez R, Serrano V, Fariñas H, Barrantes R, et al. Pharmacogenetics in Central American healthy volunteers: interethnic variability. Drug Metabol Drug Interact. 2014;30:19–31.
Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M. Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics). Drug Metab Pers Ther. 2016;31:61–81.
Suarez-Kurtz G. Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network--REFARGEN. Pharm J. 2004;4:347–8.
FDA. Table of pharmacogenomic biomarkers in drug labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed 18 Apr 2017.
Medicines Agency E. Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdf. Accessed 9 Apr 2017.
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–7.
Santana MS, de Lacerda MV, Barbosa Md, Alecrim WD, Alecrim Md. Glucose-6-phosphate dehydrogenase deficiency in an endemic area for malaria in Manaus: a cross-sectional survey in the Brazilian Amazon. PLoS ONE. 2009;4:e5259
Zapala MA, Schork NJ. Statistical properties of multivariate distance matrix regression for high-dimensional data analysis. Front Genet. 2012;3:190.
Bhinder P, Chaudhry A. Mutagenicity assessment of organophosphates using polymerase chain reaction-restriction fragment length polymorphism assay. Toxicol Int. 2013;20:254–60.
Muranli FDG, Kanev M, Ozdemir K. Genotoxic effects of diazinon on human peripheral blood lymphocytes/Genotoksično djelovanje diazinona na limfocite ljudske periferne krvi. Arch Ind Hyg Toxicol. 2015;66:153–8.
Suarez-Kurtz G, Genro JP, de Moraes MO, Ojopi EB, Pena SDJ, Perini JA, et al. Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharm J. 2012;12:267–76.
Suarez-Kurtz G, Perini JA, Bastos-Rodrigues L, Pena SDJ, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics. 2007;8:1299–306.
Suarez-Kurtz G, Vargens DD, Struchiner CJ, Bastos-Rodrigues L, Pena SDJ. Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet Genomics. 2007;17:765–71.
Suarez-Kurtz G, Vargens DD, Santoro AB, Hutz MH, de Moraes ME, Pena SDJ, et al. Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population. PLoS ONE. 2014;9:e83472.
Suarez-Kurtz G, Amorim A, Damasceno A, Hutz MH, de Moraes MO, Ojopi EB, et al. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics. 2010;11:1257–67.
Bonifaz-Peña V, Contreras AV, Struchiner CJ, Roela RA, Furuya-Mazzotti TK, Chammas R, et al. Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. PLoS ONE. 2014;9:e112640.
Friedrich DC, Genro JP, Sortica VA, Suarez-Kurtz G, de Moraes ME, Pena SDJ, et al. Distribution of CYP2D6 alleles and phenotypes in the Brazilian population. PLoS ONE. 2014;9:e110691.
Vargens DD, Almendra L, Struchiner CJ, Suarez-Kurtz G. Distribution of the GNB3 825C>T polymorphism among Brazilians: impact of population structure. Eur J Clin Pharmacol. 2008;64:253–6.
Soares RAG, Santos PCJL, Machado-Coelho GLL, do Nascimento RM, Mill JG, Krieger JE, et al. CYP2C9 and VKORC1 polymorphisms are differently distributed in the Brazilian population according to self-declared ethnicity or genetic ancestry. Genet Test Mol Biomarkers. 2012;16:957–63.
Sortica V de A, Ojopi EB, Genro JP, Callegari-Jacques S, Ribeiro-Dos-Santos A, de Moraes MO, et al. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol. 2012;110:460–8.
Santos KT, De Freitas RGA, Manta FSN, De Carvalho EF, Silva DA. Ser49Gly polymorphism in the β-adrenergic receptor 1 gene in a population sample from Rio de Janeiro state, Brazil, stratified by self-identified skin color and genetic ancestry. Mol Med Rep. 2015;12:1591–7.
Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. Br J Clin Pharmacol. 2010;70:43–51.
Cassiano NM, Oliveira RV, Bernasconi GCR, Cass QB. Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group. Chirality. 2012;24:289–93.
Rocha A, Coelho EB, Moussa SAP, Lanchote VL. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers. Eur J Clin Pharmacol. 2008;64:901–6.
Cass QB, Lima VV, Oliveira RV, Cassiano NM, Degani ALG, Pedrazzoli J. Enantiomeric determination of the plasma levels of omeprazole by direct plasma injection using high-performance liquid chromatography with achiral-chiral column-switching. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;798:275–81.
LLerena A, Naranjo MEG, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014;10:1569–83.
Côté J-F, Kirzin S, Kramar A, Mosnier J-F, Diebold M-D, Soubeyran I, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007;13:3269–75.
Yuan H-Y, Chen J-J, Lee MTM, Wung J-C, Chen Y-F, Charng M-J, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745–51.
Perini JA, Struchiner CJ, Silva-Assunção E, Santana ISC, Rangel F, Ojopi EB, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther. 2008;84:722–8.
Santana MS, Monteiro WM, Siqueira AM, Costa MF, Sampaio V, Lacerda MV, et al. Glucose-6-phosphate dehydrogenase deficient variants are associated with reduced susceptibility to malaria in the Brazilian Amazon. Trans R Soc Trop Med Hyg. 2013;107:301–6.
Egesie OJ, Joseph DE, Isiguzoro I, Egesie UG. Glucose-6-phosphate dehydrogenase (G6PD) activity and deficiency in a population of Nigerian males resident in Jos. Niger J Physiol Sci. 2008;23:9–11.
Müller SA, Amoah SKB, Meese S, Spranger J, Mockenhaupt FP. High prevalence of anaemia among African migrants in Germany persists after exclusion of iron deficiency and erythrocyte polymorphisms. Trop Med Int Health. 2015;20:1180–9.
Nguetse CN, Meyer CG, Adegnika AA, Agbenyega T, Ogutu BR, Kremsner PG, et al. Glucose-6-phosphate dehydrogenase deficiency and reduced haemoglobin levels in African children with severe malaria. Malar J. 2016;15:346.
Monteiro WM, Val FFA, Siqueira AM, Franca GP, Sampaio VS, Melo GC, et al. G6PD deficiency in Latin America: systematic review on prevalence and variants. Mem Inst Oswaldo Cruz. 2014;109:553–68.
Callegari-Jacques SM, Tarazona-Santos EM, Gilman RH, Herrera P, Cabrera L, dos Santos SEB, et al. Autosome STRs in native South America-Testing models of association with geography and language. Am J Phys Anthropol. 2011;145:371–81.
Céspedes-Garro C, Fricke-Galindo I, Naranjo M-EG, Rodrigues-Soares F, Fariñas H, de Andrés F, et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin Drug Metab Toxicol. 2015;11:1893–905.
Saldanha PH, Lebensztajn B, Itskan SB. Activity of glucose-6-phosphate dehydrogenase among Indians living in a malarial region of Mato Grosso and its implication to the Indian-mixed populations in Brazil. Hum Hered. 1976;26:241–51.
Salzano FM, Callegari-Jacques SM. South American Indians: a case study in evolution. Oxford: Clarendon Press; 1988.
Coimbra CEA, Santos RV, Welch JR, Cardoso AM, de Souza MC, Garnelo L, et al. The First National Survey of Indigenous People’s Health and Nutrition in Brazil: rationale, methodology, and overview of results. BMC Public Health. 2013;13:52.
Céspedes-Garro C, Rodrigues-Soares F, Jimenez-Arce G, Naranjo M-EG, Tarazona-Santos E, Fariñas H, et al. Relevance of the ancestry for the variability of the drug-metabolizing enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population. Rev Biol Trop. 2016; 64:1067-76.
Barbujani G, Pigliucci M. Human races. Curr Biol. 2013;23:R185–7.
Ruiz-Linares A, Adhikari K, Acuña-Alonzo V, Quinto-Sanchez M, Jaramillo C, Arias W, et al. Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet. 2014;10:e1004572.
Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004;76:18–26.
Vargens DD, Petzl-Erler M-L, Suarez-Kurtz G. Distribution of CYP2C polymorphisms in an Amerindian population of Brazil. Basic Clin Pharmacol Toxicol. 2012;110:396–400.
Perini JA, Vargens DD, Santana ISC, Moriguchi EH, Ribeiro-Dos-Santos AKC, Tsutsumi M, et al. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz J Med Biol Res. 2009;42:1179–84.
Kohlrausch FB, Carracedo Á, Hutz MH. Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians. Mol Biol Rep. 2014;41:1453–60.
Suarez-Kurtz G, Sortica VA, Vargens DD, Bruxel EM, Petzl-Erler M-L, Petz-Erler M-L, et al. Impact of population diversity on the prediction of 7-SNP NAT2 phenotypes using the tagSNP rs1495741 or paired SNPs. Pharmacogenet Genomics. 2012;22:305–9.
Acknowledgements
We thank RIBEF/MESTIFAR members for interactions, to Daniela Junqueira, Maria Clara da Silva, Maria B Lovato, and Renan P Souza for discussions.
Funding
CAPES Foundation from the Brazilian Ministry of Education, Brazilian National Research Council (CNPq), Minas Gerais State Agency for Research (FAPEMIG). The EPIGEN-Brazil Initiative was funded by the Brazilian Ministry of Health (Secretaria de Ciência, Tecnologia e Insumos Estratégicos [SCTIE]), through Financiadora de Estudos e Projetos (FINEP).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Rodrigues-Soares, F., Kehdy, F.S.G., Sampaio-Coelho, J. et al. Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative. Pharmacogenomics J 18, 749–759 (2018). https://doi.org/10.1038/s41397-018-0015-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41397-018-0015-7
This article is cited by
-
Reference values for left ventricular dimensions, systolic and diastolic function: a study from the Amazon Basin of Brazil
The International Journal of Cardiovascular Imaging (2022)
-
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts
Pharmacological Reports (2022)
-
Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians
Scientific Reports (2019)